NT-proBNP

Impact of Sacubitril/Valsartan on Lipid Parameters in Pa ents with Heart Failure with Reduced Ejection Fraction

by Prateek Chopra | May 28, 2026 | Cardiology Conferences | ESC-HF 2026 Long-term modulation of lipid metabolism with angiotensin receptor–neprilysin inhibition in heart failure with reduced ejection fraction remains incompletely characterised, despite evidence suggesting metabolic effects mediated through neprilysin inhibition and enhanced natriuretic peptide signalling. This study evaluated the longitudinal effects of sacubitril/valsartan on lipid parameters and N-terminal pro-B-type natriuretic […]

Impact of Sacubitril/Valsartan on Lipid Parameters in Pa ents with Heart Failure with Reduced Ejection Fraction Read Post »

Leave a Comment / ESC-HF Day 3 / / / , , , ,

The Prognostic Role of Regular NT-proBNP Measurement A er a Rapid-Up Titration Programme of Guideline-Directed Medical Therapy in Heart Failure: Essential or Superfluous?

by Prateek Chopra | May 25, 2026 | Cardiology Conferences | ESC-HF 2026 N-terminal pro-B-type natriuretic peptide (NT-proBNP) is an important prognostic biomarker in heart failure (HF). The 2023 ESC HF Guidelines recommend rapid up-titration (RT) of guideline-directed medical therapy (GDMT) following an index HF hospitalization; however, the prognostic significance of NT-proBNP changes after a rapid titration programme (RTP) remains uncertain.

The Prognostic Role of Regular NT-proBNP Measurement A er a Rapid-Up Titration Programme of Guideline-Directed Medical Therapy in Heart Failure: Essential or Superfluous? Read Post »

Leave a Comment / ESC-HF Day 2 / / / , , , ,

Left Ventricular Ejection on Fraction, Ventricular Remodelling and Outcomes After Sacubitril – Valsartan in a Real-Life Cohort

by Prateek Chopra | May 17, 2026 | Cardiology Conferences | ESC-HF 2026 Sacubitril–valsartan (SV) has demonstrated prognostic benefits in patients with heart failure with reduced ejection fraction (HFrEF), although its long-term impact in real-world clinical practice remains unclear. This study assessed long-term outcomes associated with SV use in a real-world HFrEF cohort. The findings were presented at Heart Failure 2026,

Left Ventricular Ejection on Fraction, Ventricular Remodelling and Outcomes After Sacubitril – Valsartan in a Real-Life Cohort Read Post »

Leave a Comment / ESC-HF Day 1 / / / , , , ,

The Prognostic Value of NT-proBNP Variability Measured During Rou ne Follow-Up in Outpatients with Heart Failure with Reduced Ejection Fraction

by Prateek Chopra | May 19, 2026 | Cardiology Conferences | ESC-HF 2026 N-terminal pro–B-type natriuretic peptide (NT-proBNP) is an established biomarker for risk stratification in Heart Failure with reduced ejection fraction (HFrEF). However, the prognostic significance of serial variability in NT-proBNP levels during routine follow-up in clinically stable patients remains unclear. This study aimed to determine whether fluctuations in NT-proBNP

The Prognostic Value of NT-proBNP Variability Measured During Rou ne Follow-Up in Outpatients with Heart Failure with Reduced Ejection Fraction Read Post »

Leave a Comment / ESC-HF Day 1 / / / , , , ,
Scroll to Top